By Type: Journal Article

Veigas, Bruno, Joana Pinto, Raquel Vinhas, Tomas Calmeiro, Rodrigo Martins, Elvira Fortunato, and Pedro Viana Baptista. "Quantitative real-time monitoring of RCA amplification of cancer biomarkers mediated by a flexible ion sensitive platform." Biosensors & Bioelectronics 91 (2017): 788-795. Abstract

n/a

Roma-Rodrigues, Catarina, Luis Raposo, Rita Cabral, Fabiana Paradinha, Pedro V. Baptista, and Alexandra R. Fernandes. "Tumor microenvironment modulation via gold nanoparticles targeting malicious exosomes: implications in cancer diagnostics and Therapy." Int. J. Mol. Sci. 18 (2017): 162. AbstractWebsite

Exosomes are nanovesicles formed in the endosomal pathway with an important role in paracrine and autocrine cell communication. Exosomes secreted by cancer cells, malicious exosomes, have important roles in tumor microenvironment maturation and cancer progression. The knowledge of the role of exosomes in tumorigenesis prompted a new era in cancer diagnostics and therapy, taking advantage of the use of circulating exosomes as tumor biomarkers due to their stability in body fluids and targeting malignant exosomes’ release and/or uptake to inhibit or delay tumor development. In recent years, nanotechnology has paved the way for the development of a plethora of new diagnostic and therapeutic platforms, fostering theranostics. The unique physical and chemical properties of gold nanoparticles (AuNPs) make them suitable vehicles to pursuit this goal. AuNPs’ properties such as ease of synthesis with the desired shape and size, high surface:volume ratio, and the possibility of engineering their surface as desired, potentiate AuNPs’ role in nanotheranostics, allowing the use of the same formulation for exosome detection and restraining the effect of malicious exosomes in cancer progression.

Raposo, L. R., C. Roma-Rodrigues, P. Faisca, M. Alves, J. Henriques, MC Carvalheiro, M. L. Corvo, P. V. Baptista, A. J. Pombeiro, and A. R. Fernandes. "Immortalization and characterization of a new canine mammary tumour cell line FR37-CMT." Veterinary and Comparative Oncology 15 (2017): 952-967. Abstract

n/a

Vinhas, Raquel, Claudia Correia, Patricia Ribeiro, Alexandra Lourenco, Aida Botelho de Sousa, Alexandra R. Fernandes, and Pedro V. Baptista. "Colorimetric assessment of BCR-ABL1 transcripts in clinical samples via gold nanoprobes." Analytical and Bioanalytical Chemistry 408 (2016): 5277-5284. Abstract

n/a

Cordeiro, Milton, Fabio Ferreira Carlos, Pedro Pedrosa, Antonio Lopez, and Pedro Viana Baptista. "Gold Nanoparticles for Diagnostics: Advances towards Points of Care." Diagnostics 6 (2016). Abstract

n/a

Mendes, Rita, Barbara Carreira, Pedro V. Baptista, and Alexandra R. Fernandes. "Non-small cell lung cancer biomarkers and targeted therapy - two faces of the same coin fostered by nanotechnology." Expert Review of Precision Medicine and Drug Development 1 (2016): 155-168. Abstract

n/a

Vinhas, Raquel, Anna Tolmatcheva, Rafaela Canto, Patricia Ribeiro, Alexandra Lourenco, Aida Botelho de Sousa, Pedro V. Baptista, and Alexandra R. Fernandes. "A novel mutation in CEBPA gene in a patient with acute myeloid leukemia." Leukemia & Lymphoma 57 (2016): 711-713. Abstract

n/a

Cordeiro, Mílton, Fábio Ferreira Carlos, Pedro Pedrosa, António Lopez, and Pedro Viana Baptista. "Gold Nanoparticles for Diagnostics: Advances towards Points of Care." Diagnostics 6 (2016): 43. AbstractWebsite

The remarkable physicochemical properties of gold nanoparticles (AuNPs) have prompted developments in the exploration of biomolecular interactions with AuNP-containing systems, in particular for biomedical applications in diagnostics. These systems show great promise in improving sensitivity, ease of operation and portability. Despite this endeavor, most platforms have yet to reach maturity and make their way into clinics or points of care (POC). Here, we present an overview of emerging and available molecular diagnostics using AuNPs for biomedical sensing that are currently being translated to the clinical setting.

Roma-Rodrigues, Catarina, Cynthia Alves-Barroco, Luis R. Raposo, Mafalda N. Costa, Elvira Fortunato, Pedro Viana Baptista, Alexandra R. Fernandes, and Ilda Santos-Sanches. "Infection of human keratinocytes by Streptococcus dysgalactiae subspecies dysgalactiae isolated from milk of the bovine udder." Microbes and Infection 18 (2016): 290-293. Abstract

n/a

Corvo, Luísa M., Ana Soraia Mendo, Sara Figueiredo, Rogério Gaspar, Miguel Larguinho, Fátima Guedes M. C. da Silva, Pedro Viana Baptista, and Alexandra R. Fernandes. "Liposomes as Delivery System of a Sn(IV) Complex for Cancer Therapy." Pharmaceutical Research (2016).
Conde, Joao, Furong Tian, Jesus M. de la Fuente, and Pedro V. Baptista. "Editorial: Cancer Nanotheranostics: What Have We Learned So Far?" Frontiers in Chemistry 71 (2016).Website
Lenis-Rojas, O. A., A. R. Fernandes, C. Roma-Rodrigues, P. V. Baptista, F. Marques, D. Perez-Fernandez, J. Guerra-Varela, L. Sanchez, D. Vazquez-Garcia, M. Lopez Torres, A. Fernandez, and J. J. Fernandez. "Heteroleptic mononuclear compounds of ruthenium(II): synthesis, structural analyses, in vivo antitumor activity and in vivo toxicity on zebrafish embryost." Dalton Transactions 45 (2016): 19127-19140. Abstract

n/a

Roma-Rodrigues, Catarina, Amelie Heuer-Jungemann, Alexandra R. Fernandes, Antonios G. Kanaras, and Pedro V. Baptista. "Peptide-coated gold nanoparticles for modulation of angiogenesis in vivo." International Journal of Nanomedicine 11 (2016): 2633-2639. Abstract

n/a

Cordeiro, Milton, Leticia Giestes, Joao Carlos Lima, and Pedro Baptista. "BioCode gold-nanobeacon for the detection of fusion transcripts causing chronic myeloid leukemia." Journal of Nanobiotechnology 38 (2016). AbstractWebsite

Background
Gold-nanobeacons (Au-nanobeacons) have proven to be versatile systems for molecular diagnostics and therapeutic actuators. Here, we present the development and characterization of two gold nanobeacons combined with Förster resonance energy transfer (FRET) based spectral codification for dual mode sequence discrimination. This is the combination of two powerful technologies onto a single nanosystem.

Results
We proved this concept to detect the most common fusion sequences associated with the development of chronic myeloid leukemia, e13a2 and e14a2. The detection is based on spectral shift of the donor signal to the acceptor, which allows for corroboration of the hybridization event. The Au-nanobeacon acts as scaffold for detection of the target in a homogenous format whose output capability (i.e. additional layer of information) is potentiated via the spectral codification strategy.

Conclusions
The spectral coded Au-nanobeacons permit the detection of each of the pathogenic fusion sequences, with high specificity towards partial complementary sequences. The proposed BioCode Au-nanobeacon concept provides for a nanoplatform for molecular recognition suitable for cancer diagnostics.

Ma, Zhen, Bian Zhang, Fátima Guedes M. C. da Silva, Joana Silva, Ana Soraia Mendo, Pedro Viana Baptista, and Alexandra R. Fernandes. "Synthesis, Characterization, Thermal Properties and Antiproliferative Potential of Copper(II) 4′-phenyl-terpyridine Compounds." Dalton Transactions 45 (2016).
Luisa Corvo, M., Ana Soraia Mendo, Sara Figueiredo, Rogerio Gaspar, Miguel Larguinho, Fatima M. C. Guedes da Silva, Pedro Viana Baptista, and Alexandra R. Fernandes. "Liposomes as Delivery System of a Sn(IV) Complex for Cancer Therapy." Pharmaceutical Research 33 (2016): 1351-1358. Abstract

n/a

Vinhas, Raquel, Milton Cordeiro, Pedro Pedrosa, Alexandra R. Fernandes, and Pedro V. Baptista. "Current trends in molecular diagnostics of chronic myeloid leukemia." Leukemia & Lymphoma (2016): 1-14. AbstractWebsite

Nearly 1.5 million people worldwide suffer from chronic myeloid leukemia (CML), characterized by the genetic translocation t(9;22)(q34;q11.2), involving the fusion of the Abelson oncogene (ABL1) with the breakpoint cluster region (BCR) gene. Early onset diagnosis coupled to current therapeutics allow for a treatment success rate of 90, which has focused research on the development of novel diagnostics approaches. In this review, we present a critical perspective on current strategies for CML diagnostics, comparing to gold standard methodologies and with an eye on the future trends on nanotheranostics.

Baptista, Pedro Viana. "Precision nanomedicine in cancer: how far are we from personalization?" Expert Review of Precision Medicine and Drug Development 1 (2016): 227-228. Abstract

n/a

Martins, Marta, Pedro V. Baptista, Ana Soraia Mendo, Claudia Correia, Paula Videira, Antonio S. Rodrigues, J. Muthukumaran, Teresa Santos-Silva, Ana Silva, Fatima M. C. Guedes da Silva, Joana Gigante, Antonio Duarte, Malgorzata Gajewska, and Alexandra R. Fernandes. "In vitro and in vivo biological characterization of the anti-proliferative potential of a cyclic trinuclear organotin(IV) complex." Molecular Biosystems 12 (2016): 1015-1023. Abstract

n/a

Martins, Pedro, Mara Marques, Lidia Coito, Armando Pombeiro, Pedro V. Baptista, and Alexandra R. Fernandes. "Organometallic Compounds in Cancer Therapy: Past Lessons and Future Directions." ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY 9 (2015). AbstractWebsite

Over the past few years, modern medicinal chemistry has evolved towards providing us new and alternative chemotherapeutic compounds with high cytotoxicity towards tumor cells, alongside with reduced side effects in cancer patients. Organometallic compounds and their unique physic-chemical properties typically used in homogenous catalysis are now being translated as potential candidates for medical purposes. Their structural diversity, ligand exchange, redox and catalytic properties make them promising drug candidates for cancer therapy. Over the last decade this area has witnessed a steady growth and a few organometallic compounds have in fact already entered clinical trials, emphasizing its increasing importance and clinical relevance. Here we intend to stress out the different applications of organometallic compounds in medicine with emphasis on cancer therapy, as well as address setbacks regarding formulation issues, systemic toxicity and off-target effects. Advantages over classical coordination metal complexes, their nanovectorisation and specific molecular targets are also discussed.

Vinhas, R., C. Correia, P. Ribeiro, A. Lourenco, A. Sousa, A. Fernandes, and P. Baptista. "GOLD NANOPROBES IN THE DIAGNOSTIC OF CHRONIC MYELOID LEUKEMIA: DETECTION OF THE E14A2 BCR-ABL TRANSCRIPT DIRECTLY IN RNA SAMPLES." Leukemia Research 39 (2015): S90. Abstract

n/a

Bernacka-Wojcik, Iwona, Hugo Aguas, Fabio Ferreira Carlos, Paulo Lopes, Pawel Jerzy Wojcik, Mafalda Nascimento Costa, Bruno Veigas, Rui Igreja, Elvira Fortunato, Pedro Viana Baptista, and Rodrigo Martins. "Single Nucleotide Polymorphism Detection Using Gold Nanoprobes and Bio-Microfluidic Platform With Embedded Micro lenses." Biotechnology and Bioengineering 112 (2015): 1210-1219. Abstract

n/a

Conde, Joao, Furong Tian, Yulan Hernandez, Chenchen Bao, Pedro V. Baptista, Daxiang Cui, Tobias Stoeger, and Jesus M. de la Fuente. "RNAi-based glyconanoparticles trigger apoptotic pathways for in vitro and in vivo enhanced cancer-cell killing." Nanoscale 7 (2015): 9083-9091. Abstract

n/a

McCully, Mark, Yulan Hernandez, Joao Conde, Pedro V. Baptista, Jesus M. de la Fuente, Andrew Hursthouse, David Stirling, and Catherine C. Berry. "Significance of the balance between intracellular glutathione and polyethylene glycol for successful release of small interfering RNA from gold nanoparticles." Nano Research 8 (2015): 3281-3292. Abstract

n/a

Child, Hannah Winifred, Yulan Hernandez, João Conde, Margaret Mullin, Pedro V. Baptista, Jesus Maria de la Fuente, and Catherine C. Berry. "Gold nanoparticle-siRNA mediated oncogene knockdown at RNA and protein level, with associated gene effects." NANOMEDICINE 10 (2015): 2513-2525. AbstractWebsite

Aims: RNAi is a powerful tool for gene silencing that can be used to reduce undesirable overexpression of oncogenes as a novel form of cancer treatment. However, when using RNAi as a therapeutic tool there is potential for associated gene effects. This study aimed to utilize gold nanoparticles to deliver siRNA into HeLa cells. Results: Knockdown of the c-myc oncogene by RNAi, at the RNA, protein and cell proliferation level was achieved, while also identifying associated gene responses. Discussion: The gold nanoparticles used in this study present an excellent delivery platform for siRNA, but do note associated gene changes. Conclusion: The study highlights the need to more widely assess the cell physiological response to RNAi treatment, rather than focus on the immediate RNA levels.